Charles River Laboratories International Inc. (NYSE:CRL) has been given a $93.00 price target by analysts at Bank of America Corp. in a research note issued to investors on Friday. The firm presently has a “buy” rating on the stock. Bank of America Corp.’s price target points to a potential upside of 28.38% from the stock’s previous close.

A number of other research firms have also recently commented on CRL. Zacks Investment Research cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Friday, July 22nd. Evercore ISI reaffirmed a “hold” rating and set a $91.50 price objective (up from $83.50) on shares of Charles River Laboratories International in a research report on Thursday, August 4th. Jefferies Group lifted their price objective on shares of Charles River Laboratories International from $94.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, August 4th. Citigroup Inc. lifted their price objective on shares of Charles River Laboratories International from $85.00 to $90.00 and gave the stock a “neutral” rating in a research report on Thursday, August 4th. Finally, Credit Suisse Group AG reaffirmed a “neutral” rating on shares of Charles River Laboratories International in a research report on Friday, September 30th. Two research analysts have rated the stock with a sell rating, six have given a hold rating and five have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $84.96.

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Shares of Charles River Laboratories International (NYSE:CRL) opened at 72.44 on Friday. The firm has a market cap of $3.43 billion, a PE ratio of 24.48 and a beta of 1.18. The company’s 50 day moving average is $77.44 and its 200-day moving average is $82.13. Charles River Laboratories International has a 12 month low of $65.70 and a 12 month high of $89.18.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 2nd. The company reported $1.18 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.13 by $0.05. The business had revenue of $425.70 million for the quarter, compared to the consensus estimate of $291.20 million. Charles River Laboratories International had a net margin of 9.05% and a return on equity of 25.11%. The firm’s revenue for the quarter was up 21.8% on a year-over-year basis. During the same period in the previous year, the company earned $1.03 earnings per share. Equities research analysts predict that Charles River Laboratories International will post $4.47 EPS for the current year.

In related news, insider Davide Molho sold 7,877 shares of the company’s stock in a transaction dated Tuesday, August 30th. The shares were sold at an average price of $84.10, for a total transaction of $662,455.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 2.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Emerald Acquisition Ltd. acquired a new position in shares of Charles River Laboratories International during the second quarter valued at approximately $37,018,000. FMR LLC increased its position in shares of Charles River Laboratories International by 19.5% in the second quarter. FMR LLC now owns 2,158,477 shares of the company’s stock valued at $177,945,000 after buying an additional 351,630 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of Charles River Laboratories International by 124.2% in the second quarter. Principal Financial Group Inc. now owns 497,895 shares of the company’s stock valued at $41,047,000 after buying an additional 275,785 shares during the last quarter. Redwood Investments LLC acquired a new position in shares of Charles River Laboratories International during the second quarter valued at approximately $14,493,000. Finally, Fiera Capital Corp acquired a new position in shares of Charles River Laboratories International during the second quarter valued at approximately $14,424,000. 95.96% of the stock is owned by hedge funds and other institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a full service, early-stage contract research company. The Company is engaged in the business of providing the research models required in research and development of new drugs, devices and therapies. The Company operates through three segments: Research Models and Services (RMS), which consists of Research Models and Research Model Services; Discovery and Safety Assessment (DSA), which offers discovery and safety assessment services, both regulated and non-regulated, in which it includes both in vivo and in vitro studies, and Manufacturing Support (Manufacturing), which includes Microbial Solutions, Biologics Testing Solutions and Avian Vaccine Services.

5 Day Chart for NYSE:CRL

Receive News & Stock Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related stocks with our FREE daily email newsletter.